Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,382 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Colorectal Neoplasia Clear all
Completed No phase listed Observational

Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy

NCT00442520
View directory record Official record
Conditions
Lung Cancer, Colorectal Cancer, Head and Neck Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NCT04068896
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions
NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Phase 1 Interventional

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

NCT00543842
View directory record Official record
Conditions
Rectal Cancer
Interventions
Bevacizumab, Capecitabine, Erlotinib, Radiation Therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Jun 7, 2026, 1:31 PM EDT
Recruiting Phase 2 Interventional

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

NCT07130903
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma
Interventions
Fruquintinib, TheraBionic P1
Drug · Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
22 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
9
States / cities
Bay City, Michigan • Clarkston, Michigan • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 7, 2026, 1:31 PM EDT
Terminated Phase 2 Interventional Results available

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

NCT00216086
View directory record Official record
Conditions
Rectal Cancer
Interventions
Capecitabine, Irinotecan, EUS, Neoadjuvant Chemotherapy, Preoperative Radiation, Surgery, Adjuvant Chemotherapy
Drug · Procedure
Lead sponsor
Gabi Chiorean, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

NCT03414983
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Nivolumab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People

NCT04336397
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Multi-target stool DNA test, Colonoscopy
Diagnostic Test
Lead sponsor
Alaska Native Tribal Health Consortium
Other
Eligibility
45 Years to 75 Years
Enrollment
2,029 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethel, Alaska
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

NCT04474470
View directory record Official record
Conditions
Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor, Recurrent Solid Tumor, Head and Neck Cancer
Interventions
NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion
Drug
Lead sponsor
TyrNovo Ltd.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Encinitas, California • Los Angeles, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

NCT04426669
View directory record Official record
Conditions
Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal, Gastrointestinal Cancer, Colo-rectal Cancer, Pancreatic Cancer, Gall Bladder Cancer, Colon Cancer, Esophageal Cancer, Stomach Cancer
Interventions
Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin
Drug · Biological
Lead sponsor
Intima Bioscience, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 7, 2026, 1:31 PM EDT
Recruiting Phase 1Phase 2 Interventional

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

NCT03539822
View directory record Official record
Conditions
Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
Interventions
Cabozantinib, Durvalumab, Tremelimumab
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
2
States / cities
Westwood, Kansas • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Phase 1Phase 2 Interventional

SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia

NCT00052897
View directory record Official record
Conditions
Anal Cancer
Interventions
HspE7
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use and Decision-making About Colorectal Cancer Screening Among Hispanic Men and Women

NCT00136227
View directory record Official record
Conditions
Colorectal Cancer
Interventions
small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
50 Years and older
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Results available

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

NCT05064059
View directory record Official record
Conditions
Colorectal Cancer
Interventions
favezelimab/pembrolizumab, regorafenib, TAS-102
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 7, 2026, 1:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Computer-Based Tailored or Standard Information for Colorectal Cancer Screening

NCT00955188
View directory record Official record
Conditions
Colorectal Cancer
Interventions
computer-assisted intervention, educational intervention, medical chart review
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
50 Years to 79 Years
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
3
States / cities
San Francisco, California • Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Not applicable Interventional

Predicting and Addressing Colonoscopy in Safety Net Settings

NCT03925883
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Patient navigation
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years to 75 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Jun 7, 2026, 1:31 PM EDT
Terminated No phase listed Observational

Freehand Ultrasound Elasticity Imaging in Liver Surgery

NCT00942383
View directory record Official record
Conditions
Liver Tumors
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

NCT03631407
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Vicriviroc, Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Scottsdale, Arizona • Encinitas, California • Fresno, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jun 7, 2026, 1:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"

NCT04144751
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Blood Sample Collection
Other
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
40 Years and older
Enrollment
23,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
194
States / cities
Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 160 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jun 7, 2026, 1:31 PM EDT
Recruiting Phase 1 Interventional

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

NCT03692429
View directory record Official record
Conditions
Unresectable Metastatic Colorectal Cancer
Interventions
CYAD-101, FOLFOX, FOLFIRI
Drug
Lead sponsor
Celyad Oncology SA
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Phase 1 Interventional

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

NCT00739453
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-906, erlotinib
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

R-21 Colorectal Cancer Screening (CRCS) Pilot Trial

NCT01492049
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
CRCS patient decision aid (PtDA) video, Questionnaires, Essential Hypertension video
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
49 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Jun 7, 2026, 1:31 PM EDT
Active, not recruiting Phase 2 Interventional

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma, Carcinoma Arising From Spiradenoma, Digital Papillary Adenocarcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Extramammary Paget Disease, Extraocular Sebaceous Carcinoma, Hidradenocarcinoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Adenocarcinoma, Skin Adenoid Cystic Carcinoma, Skin Adnexal Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Keratoacanthoma, Skin Squamous Cell Carcinoma, Squamoid Eccrine Ductal Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Nivolumab, Positron Emission Mammography, Talimogene Laherparepvec
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
36
States / cities
Los Angeles, California • Orange, California • Pasadena, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Phase 1 Interventional

Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment

NCT00449137
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Arsenic trioxide, Fluorouracil, Leucovorin calcium, Plasma levels of elemental arsenic, Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis, Tumor Biopsy (Fine-Needle Aspiration)
Drug · Other · Genetic + 1 more
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Jun 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional Results available

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

NCT01298570
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
Regorafenib (BAY 73-4506), FOLFIRI, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
23
States / cities
Denver, Colorado • Miami, Florida • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Jun 7, 2026, 1:31 PM EDT